Recombinant Human Annexin V / ANX5 Protein

Beta LifeScience SKU/CAT #: BLPSN-0219

Recombinant Human Annexin V / ANX5 Protein

Beta LifeScience SKU/CAT #: BLPSN-0219
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag N/A
Host Species Human
Accession P08758
Synonym ANX5, ENX2, HEL-S-7, PP4, RPRGL3
Background The placental anticoagulant protein Annexin A5 (ANXA5) is a multifunctional protein that is highly expressed on the apical surfaces of syncytiotrophoblasts, and plays an important role in haemostatic regulations, maintaining blood fluidity of the placenta. Annexin A5 (ANXA5) is a protein abundantly expressed in normal placenta where it contributes to the healthy outcome of a pregnancy. Lower ANXA5 levels have been observed in M2/ANXA5 haplotype carrying chorion. The association found between the maternal carriage of the M2/ANXA5 haplotype and an elevated risk of IUGR and/or PE supports the hypothesis that carrier status of this haplotype and the consequently reduced placental ANXA5 expression might be responsible, at least partially, for the onset of these gestational vascular complications. ANXA5 could be used as a biomarker for the early detection of PE and for the prediction of its severity. ANXA5 as an embryonic anticoagulant that appears deficient in contiguous specter of thrombophilia-related pregnancy complications culminating more frequently in miscarriage in a maternal M2 carrier background. As a potential indicator for malignancy and lymphatic metastasis, ANXA5 overexpression increases in vitro migration and invasion of Hca-P cell, promotes in vivo malignancy, LNM rate and level of Hca-P-transplanted mice. Hereditary thrombophilias can impair vascular placental functions and predispose to the birth of small-for-gestational age (SGA) babies. The placental anticoagulant protein annexin A5 (ANXA5) may contribute to this process. A functional haplotype (M2) within the ANXA5 gene is associated with fetal loss and venous thrombosis.
Description A DNA sequence encoding the human ANXA5 (P08758) (Met 1-Asp 320) was expressed and purified.
Source E.coli
Predicted N Terminal Met 1
AA Sequence Met 1-Asp 320
Molecular Weight The recombinant human ANXA5 consisting of 320 a.a. and has a calculated molecular mass of 35.9 kDa. It migrates as an 34 kDa band in SDS-PAGE under reducing conditions.
Purity >90% as determined by SDS-PAGE
Endotoxin Please contact us for more information.
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile 50mM Tris, 240mM NaCl, pH 8.5.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.
Protein Families Annexin family
Database References
Associated Diseases Pregnancy loss, recurrent, 3 (RPRGL3)

Gene Functions References

  1. AnxA5 2D-network mediates E-cadherin mobility in the plasmalemma that triggers human trophoblasts aggregation and thereby cell fusion. PMID: 28176826
  2. Caspase-3 and -8 and annexin V may serve as diagnostic markers in Ovarian cancer , also explained that the decrement in control of the S phase in the cell cycle may considered one of the significant factors in the development of ovarian tumors PMID: 30197345
  3. When ANXA5 expression increased, cell proliferation was inhibited by regulating the expression of bcl-2 and bax while cell metastasis was suppressed by regulating E-cadherin and MMP-9 expression. PMID: 30010106
  4. Maternal carriers of the ANXA5 M2 haplotype has greater risk of developing placenta-mediated pregnancy complications, such as preeclampsia and intrauterine growth restriction. PMID: 29497952
  5. The domain IV-truncated form of anxA5 is impaired in binding phosphatidylserine liposome and apoptotic cells, and anticoagulation activity. PMID: 29257055
  6. increase in VEGF and Apelin, and decrease in Annexin A5 supports roles of hemo-dynamic alterations in fetoplacental circulation and structural alterations in uteroplacental bed occurring in preeclampsia. PMID: 29208172
  7. In patients with colon cancer, annexin A5 expression in cancer tissues is related to lymph node metastasis and tumor grade. Serum level of annexin A5 is related to annexin A5 expression in cancer tissues. PMID: 29093625
  8. annexin A5 anticoagulant has a role in adverse outcomes in antiphospholipid antibody positive patients with thrombosis or pregnancy complications PMID: 28393472
  9. There was no significant difference in circulating ANXA5 levels between subjects of the non-pregnant, RPL and parous groups (median, 0.25 ng/ml vs. 0.21 ng/ml vs. 0.01 ng/ml, p = 0.14) (Fig. 1A ). Similarly, no significant differences in circulating ANXA5 levels were observed across these three clinical subgroups among M2-carriers or non-carriers, respectively. PMID: 28605660
  10. Serum annexin A5 level was not altered in pre-eclampsia. PMID: 28501283
  11. Annexin A5 was proposed to use in detection of apoptosis. associated with the Breast Cancer. Upregulation of the AA5 protein is detected in Pleomorphic Adenoma of the Parotid Gland. PMID: 28497265
  12. Physiological function of ANXA5 as an embryonic anticoagulant that appears deficient in contiguous specter of thrombophilia-related pregnancy complications culminating more frequently in miscarriage in a maternal M2 carrier background. PMID: 28900802
  13. This study confirmed the proposed role of M2/ANXA5 as embryonic, genetically associated thrombophilia predisposition factor for early recurrent pregnancy loss among ethnic Malay of Malaysia. PMID: 28108842
  14. Circulating anxA5 levels are associated with carotid intima-media thickness but not coronary plaque composition in high-risk patients with diabetes mellitus. PMID: 28592134
  15. Results showed that ANXA5 rs1050606 was significantly associated with left ventricular hypertrophy in Chinese endogenous hypertension patients. PMID: 29095261
  16. Moreover, mechanism study exhibited that Annexin A5 could activate PI3K/Akt/mTOR signaling pathway, promote epithelial-mesenchymal transition (EMT) and the expression of MMP2 and MMP9. Annexin A5 may be a potential prognostic biomarker in RCC and promotes proliferation, migration and invasion of RCC cells via activating PI3K/Akt/mTOR signaling pathway and regulating EMT process and MMP expression. PMID: 28393205
  17. human myotubes rendered deficient for Annexin-A5 (AnxA5) suffer from a severe defect in membrane resealing. PMID: 27286750
  18. This study functionally characterized allelic variants in the ANXA5 promoter, both alone and in combinations, and the results suggest that combinations of several individual variants contribute to modulate the ANXA5 transcriptional activity, most likely through binding of nuclear factors. PMID: 27318245
  19. Chronically increased alveolar annexin V levels, as reflected in increased idiopathic pulmonary fibrosis (IPF) BALF levels, may contribute to the progression of IPF by inducing the release of pro-fibrotic mediators. PMID: 26160872
  20. lower exhaled breath condensate annexin A5 levels in children with exercise-induced asthma compared to non-exercised-induced one PMID: 25796304
  21. The M2 haplotype is a risk factor for early spontaneous abortions, before the 12th week of gestation, and confers about the same relative risk to carriers of both sexes. PMID: 26371709
  22. annexin A5 promoter haplotype M2 may not have a role in recurrent pregnancy loss in Estonia or Denmark PMID: 26135579
  23. Annexin V is fused to an enzyme, creating a fusion protein that converts nontoxic drug precursors, prodrugs, into anticancer compounds while bound to the tumor, therefore mitigating the risk of side effects. PMID: 25899647
  24. Neither the M1/M2 haplotypes nor the tag SNPs in ANXA5 were convincingly associated with pregnancy related venous thromboembolism. PMID: 25495894
  25. Anx5 could protect cardiomyocytes adherens junctions and improve myocardial contractile function via regulation of p120 and anti-inflammation in LPS-induced endotoxemia. PMID: 25799159
  26. The associated male partner risk confirms the proposed role of M2/ANXA5 as a genetic trait impeding embryonic anticoagulation. PMID: 25682309
  27. AnxA5 promotes membrane resealing of injured human trophoblasts. PMID: 25595530
  28. ANXA5 haplotypes/plasma ANXA5 levels were not associated with carotid IMT progression or cardiovascular disease risk in familial hypercholesterolemia patients. PMID: 25525746
  29. The prognostic value of AnV and T cell apoptosis was evaluated in children with nephrotic syndrome in this review. PMID: 25661914
  30. study found neither individual SNPs nor any of the four haplotypes within the ANXA5 gene upstream region were associated with deep venous thrombosis in the Dutch population PMID: 25382354
  31. Lower incidence of M2/ANXA5 carriage in recurrent pregnancy loss patients with elevated lipoprotein(a) levels. PMID: 24335248
  32. Polycystic ovary syndrome subjects showed increased annexin V positive microparticle concentrations compared with healthy volunteers. PMID: 25336711
  33. Annexin A5 inhibits DLBCL cell invasion, MMP-9 expression/activity, and chemoresistance to CHOP through a PI3K-dependent mechanism. PMID: 25323007
  34. Data show involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma PMID: 24743186
  35. annexin A5 promotes GBM cell invasion, MMP-2 expression/activity, and chemoresistance to temozolomide through a PI3K-dependent mechanism. PMID: 25245332
  36. Modified forms of LDL activate human T cells through dendritic cells. Annexin A5 inhibits these effects and promotes induction of regulatory T cells. PMID: 25395618
  37. The annexin 5 in serums of pregnant women and patients with particular types of cancer PMID: 25080795
  38. This review describes the structure, function and genetic expression of ANXA5, as well as its possible implication in recurrent pregnancy loss. PMID: 24152411
  39. We could not prove any association of ANX5 antibodies and systemic lupus erythematosis. PMID: 24872142
  40. genetic association studies in population in Japan: Data suggest that hypomorphic alleles in ANXA5 promoter in placenta (that is, fetal alleles), but not in maternal blood, contributes to onset of pre-eclampsia. PMID: 24140079
  41. This study demonstrated the significant changes in AnxV levels and its function in type 1 diabetic patients. PMID: 24423325
  42. Annexin A5 binds in a cooperative manner to to phosphatidylserine on apoptotic cell membranes. Shrunken apoptotic cells showed the highest Hill coefficient values. PMID: 24304966
  43. frequency of annexin A5 (-1C/T) polymorphism was higher in systemic lupus erythematosus related groups but did not correlate with recurrent pregnancy loss (RPL) or annexin A5 level; anti-annexin A5 IgM level was higher among antiphospholipid syndrome patients and was associated with RPL PMID: 24600987
  44. Annexin-V modified substrate was constructed via layer-by-layer (LBL) method for specific capture of early stage apoptotic Jurkat cells. PMID: 24021657
  45. annexin A5 may play a crucial role in cisplatin-induced toxicity by mediating the mitochondrial apoptotic pathway via the induction and oligomerization of VDAC. PMID: 24318879
  46. Suggest that annezin A5 IgG plays a significant role in producing a hypercoagulable state in primary and secondary antiphospholipid syndrome. PMID: 23981755
  47. Variations within the ANXA5 gene upstream region were confirmed to be risk factors of recurrent pregnancy loss. PMID: 23850300
  48. rs11575945 polymorphism of the annexin-A5 gene is associated with schizophrenia, and its minor allele is responsible for higher levels of the annexin-A5 protein in the blood and represent one of the risk factors for this disease PMID: 24466757
  49. ANXA5 M2 haplotpye appears as an recurrent pregnany loss risk factor in male and female carriers with most distinguishable effects between the 10th and 15th week of gestation. PMID: 23899942
  50. It appears that the haplotype M2/ANXA5 is not associated with the presence of anti-trophoblast antibodies. PMID: 23529182


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed